Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN-02: ALX148 + azacitidine in higher-risk MDS
2024-513993-23-00Phase 2Completed
- Sponsor
- ALX Oncology
- Start
- Jun 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of evorpacept in myelodysplastic syndrome (MDS), sponsored by ALX Oncology. Primary endpoints: Dose-limiting toxicities in cycle 1 (phase 1 dose escalation), Safety and tolerability (phase 1 dose expansion) and 1 more. Started Jun 2024; status: completed.
02
Drugs
evorpacept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-513993-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513993-23-00.